Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand ...
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...
Canopy, the leader in Enterprise AI for oncology, today announced two abstracts selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies ...
According to MarketsandMarketstm, the military drones market is estimated at USD 34.85 billion in 2026 and is projected to reach USD 109.22 billion by 2031, registering a CAGR of 25.7% during the ...
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics ...
Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...
A new experiment is seeking to validate whether living cancer samples can be prepared, operated, monitored, and recovered ...
RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP ...
Spot and Tubular data show prescription immunology brands continued to dominate TV, while seasonal OTC brands found scale on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results